Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537007 | 0.91 | MAOB (0.46) | FFAR1FFAR4MAOBPTGESMRGPRX4 | |
| SCHEMBL547303 | 0.90 | LTA4H (0.51) | FFAR1FFAR4MAOBPARP15PARP14 | |
| SCHEMBL10584101 | 0.83 | NR4A1 (0.57) | FFAR1FFAR4MAOBPARP10PPARG | |
| SCHEMBL15610228 | 0.77 | KYNU (0.50) | — | |
| SCHEMBL1586340 | 0.77 | SLC1A3 (0.54) | — | |
| SCHEMBL10590437 | 0.76 | KMT2A (0.60) | FFAR1MAOBNR4A2 | |
| SCHEMBL8009506 | 0.76 | MTNR1A (0.55) | FFAR1MAOBMRGPRX4 | |
| SCHEMBL9077243 | 0.75 | MEN1 (0.49) | PPARGPPARARXRARXRB | |
| SCHEMBL5089141 | 0.74 | FFAR1 (0.48) | FFAR1FFAR4MAOBMRGPRX4 | |
| Hydrochloric Acid SCHEMBL5098915 | 0.73 | FFAR1 (0.47) | FFAR1FFAR4MAOBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110601-B2 | Compound, α1 adrenergic receptor antagonistic agent, and composition | SUNTORY HOLDINGS LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100004328-A1 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION | SUNTORY HOLDING LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128148-A1 | COMPOUND, ALPHA 1 ADRENALINE RECEPTOR ANTAGONIST, AND COMPOSITION | Suntory Holdings Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004328-A1 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION | ADRB1, ADRA1A, ADRA1D | FFAR1 57/4885FFAR4 271/4885MAOB 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.